Laura Beretta
Department of Molecular and Cellular Oncology, Division of Basic Sciences
Present Title & Affiliation
Primary Appointment
Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1989 | University of Paris 6, Paris, FRA, PHD, Molecular and Cellular Pharmacology |
| 1985 | University of Paris 6, Paris, FRA, DEA, Molecular and Cellular Pharmacology |
| 1984 | University of Paris 6, Paris, FRA, MS, Physiology |
| 1983 | University of Paris 6, Paris, FRA, BS, Cellular Biology and Physiology |
Postgraduate Training
| 1992-1995 | Postdoctoral Fellowship, McGill University, Montreal |
Selected Publications
Peer-Reviewed Articles
- Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55(2):483-90, 2012. e-Pub 2011. PMID: 21953299.
- Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, Campbell JS, Beretta L. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7(6):e1002147, 2011. e-Pub 2011. PMID: 21731504.
- Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6(8):e23937, 2011. e-Pub 2011. PMID: 21886843.
Grant & Contract Support
| Title: | Biomarkers for the Early Detection of Hepatocellular Carcinoma |
| Funding Source: | McCombs Institute Center MD Anderson Cancer Center |
| Role: | Principal Investigator |
| Title: | Imaging and early detection of Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | HCC Genomics in the Hispanic population of Texas |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| Title: | Prevention of Hepatocellular Carcinoma (HCC) associated with Non-Alcoholic Steatohaptitis (NASH) |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Modeling the Risk of Significant Liver Fibrosis in Obesity and Diabetes |
| Funding Source: | MD Anderson Cancer Center (MDACC-MRP) |
| Role: | Principal Investigator |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Contact PI, Admin Core Dir, Co-Leader Project 3 |
| Title: | Targeting STAT3 to Prevent Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH) |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |